CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium

• $89 million revenue in 2025 with 36% YoY growth and 88% gross margins, plus $159 million cash and 31 consecutive quarters of sequential growth — yet only ~3% penetration (647 of ~6,000 U.S. hospitals), signaling substantial upside.

• CeriBell expanded its platform with pediatric/neonatal algorithm clearance and an infant head cap (launch planned in Q2), received FDA clearance for delirium in Nov 2025 and raised its TAM to about $3.5 billion, and secured an FDA breakthrough designation for stroke in Jan 2026.

• The commercial model combines ~25% subscription revenue (≈97% gross margin) and ~75% disposable headbands, while go-to-market investments expanded territory coverage from ~35 to 55 and achieved FedRAMP clearance to enable VA sales.

• Interested in CeriBell, Inc.? Here are five stocks we like better.

CeriBell (NASDAQ:CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the 47th Annual Raymond James Institutional Investors Conference.

Blumberg told investors the company ended 2025 with $89 million in revenue, representing 36% year-over-year growth, and delivered 88% gross margins for the year. CeriBell’s commercial focus has been seizure detection in acute care settings such as the ICU and emergency department, which Blumberg described as an approximately $2 billion total addressable market. He added that the company reached multiple milestones during 2025 aimed at expanding its opportunity, including algorithm expansion to neonatal and pediatric patients and a first clearance related to delirium detection, which he said increased CeriBell’s total addressable market to about $3.5 billion.

→ Uber and Joby Aviation Team Up: Game Changer or Hype?

Blumberg positioned CeriBell’s technology as addressing a critical challenge in diagnosing non-convulsive seizures in acute care. In contrast to epilepsy-related seizures that are often visible, seizures in ICU and ED settings are frequently non-convulsive, can persist for hours or days, and can be life-threatening. He said 92% of seizures in these patients are non-convulsive, making EEG the only way to diagnose them.

He emphasized the importance of time-to-diagnosis in cases of prolonged seizure activity, including “status epilepticus,” which he described as a society-defined term for a seizure lasting five minutes or more. Delays can worsen outcomes, and he noted that first-line treatment effectiveness declines as time passes, citing a one-hour delay as materially reducing effectiveness.

→ Costco Wholesale: Buy Now, Get Paid Later as Cash and Returns Build

Blumberg said professional guidelines have increasingly recognized the need for rapid EEG-based detection, citing Neurocritical Care Society recommendations from 2012 calling for diagnosis within 15–60 minutes when status epilepticus is suspected, and similar recognition from the American Heart Association in 2020 and the American Stroke Association in 2021 and 2022.

He argued conventional EEG workflows were designed for outpatient epilepsy diagnosis and are poorly suited for urgent acute care needs because they require specialized technicians for setup and neurologist interpretation—resources that may not be available overnight or on weekends. CeriBell’s approach, he said, reduces signal acquisition to roughly five minutes and enables continuous monitoring.

→ Amprius Stock Price Gets Amped by Hyper Growth Outlook

The system uses a single-patient disposable headband (and a newly introduced head cap for babies) connected to a reusable recorder. Data is sent via hospital Wi-Fi to the cloud, allowing neurologists to access raw EEG remotely. On top of that, CeriBell’s Clarity algorithm provides bedside seizure detection and alerts, translating complex EEG traces into an easier-to-interpret “seizure burden” trend line that indicates how much time a patient has spent in seizure over the prior five minutes.

Blumberg said CeriBell recently received clearance for use in patients under 18, enabling the company to offer its seizure detection algorithm for pediatric patients. He said the physical form factor had been available previously, but the algorithm had not. The company also introduced a specialized head cap for infants.

He described this as roughly a $400 million market expansion opportunity. CeriBell has been piloting pediatric and neonatal use at sites within its installed base and is preparing for a launch planned for Q2.

In neonates, he said, the need can be even more acute: seizures remain common and largely non-convulsive, clinicians can struggle to identify seizures empirically, and guidelines may recommend EEG even without direct clinical evidence when risk factors are present. Blumberg said one hour of seizure in this population can lead to significant and potentially permanent neurocognitive impairment.

CeriBell’s business model includes two revenue streams:

• Subscription revenue: a fixed monthly fee covering hardware access and software/AI; about 25% of revenue at roughly 97% gross margin, according to Blumberg.

• Disposable headbands/head caps: typically used for a single patient and then discarded between patients; about 75% of revenue.

Blumberg said the model supports predictability and highlighted that the company has produced 31 consecutive quarters of sequential growth. Despite that trajectory, he said CeriBell is only about 3% penetrated in the U.S. seizure market. The company is currently installed in about 647 hospitals out of an estimated 6,000 U.S. hospitals with an ICU or emergency department. He also said penetration within existing accounts is around 30%, and that top users—when controlling for hospital size—use the product about three times more than average users, which management views as an opportunity to drive deeper utilization.

On go-to-market execution, Blumberg said the company expanded its territory manager coverage from roughly 35 territories in mid-2024 to 55 by Q3 2025, with those hires becoming productive in 2026. He also cited FedRAMP clearance enabling sales within the VA system.

Blumberg framed CeriBell’s longer-term vision in three horizons, starting with becoming the standard of care for seizure detection in acute care, then making “EEG a vital sign” by layering additional algorithms onto the platform to help clinicians differentiate among conditions that present similarly in altered patients.

He said the company received FDA clearance for delirium in November 2025 and is preparing a New Technology Add-on Payment submission, which may support reimbursement. He described delirium as “acute brain failure,” affecting roughly 3 million U.S. patients each year, approximately 30% of ICU patients and about 80% of mechanically ventilated patients. Blumberg said every day in delirium in the ICU carries around a 10% increase in mortality rate, and that ICU delirium survivors have about a 60% chance of developing dementia after discharge.

He said there is currently no approved device diagnostic for delirium and described CAM-ICU as the current standard—an assessment protocol that can be effective when used perfectly but may be difficult to implement consistently in chaotic ICU conditions. CeriBell is running a delirium pilot this year and expects a full launch late this year or in Q1 next year.

For stroke, Blumberg said the company received FDA breakthrough designation announced in January 2026, which can provide expedited review and a potential path to reimbursement. He noted the company had to submit early technical feasibility data and that the FDA determined the approach met criteria as a novel, life-saving technology. He said CeriBell still plans to progress through clinical and regulatory pathways for stroke.

In a Q&A session, Blumberg addressed why adoption is not higher, pointing to the complexity of changing long-established EEG workflows and aligning multiple hospital stakeholders, including ICU and ED physicians, nurses, neurologists, and hospital leadership focused on cost. He described the sales cycle as lengthy but said that once implemented, accounts require little maintenance and adoption can be difficult for competitors to displace.

He said high-utilization accounts typically have strong internal advocacy, effective workflow design (including order sets), budget ownership closer to bedside clinicians, and broader departmental deployment. Blumberg also said the company shifted from positioning the product as primarily a “night and weekend” solution earlier in its commercialization to targeting broader use as a frontline tool.

On competition, Blumberg said CeriBell is the category creator and market leader, with competitors active in the space for multiple years. He said the company is still winning business and not losing accounts, and argued that CeriBell’s algorithm capabilities, data, and planned multi-indication platform approach contribute to its competitive position.

On operating leverage and profitability, Blumberg said most sales infrastructure investment is directed toward growth, with territory managers focused on bringing accounts from initial approach through launch and then handing them off. He said clinical account managers also focus largely on growth, including department expansion and protocol best practices, with minimal “babysitting” or case coverage. He added that the company had $159 million in capital post-IPO and described cash burn as “reasonable,” emphasizing a goal of maintaining flexibility without needing to raise additional capital.

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

The article “CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium” was originally published by MarketBeat.